Nanotechnology for cancer therapy: EU project leaded by Álvaro Somoza
SBE member and scientist from IMDEA Nanoscience, Álvaro Somoza leads the recently awarded Industrial Leadership EU project (Horizon 2020) NoCanTher
The efficacy, safety and non-toxicity of this therapy have already been proven through in vitro studies.
The project, financed with more than € 7 million, aims at translating nanoformulations, previously developed at IMDEA Nanoscience, to early clinical development (phase I) for treatment of pancreatic cancer. The nanodrug consists on multi-functionalized magnetic nanoparticles, which are modified with a therapeutic agent and a targeting peptide. This allows both, intracellular drug delivery and the use of magnetic hyperthermia, as synergistic strategies to kill tumor cells.
NoCanTher will be financed 100% by the EU (program H2020-NMP-2015) and continues the efforts of a previous project (MULTIFUN) also scientifically coordinated at IMDEA Nanoscience. This time, it integrates a consortium of research centres, hospitals and enterprises from Spain, France, Germany, UK and Ireland. Among the rest of participants are the Spanisn National Cancer Research centre – CNIO and Vall d’Hebron Hospital (Spain), Trinity College Dublin (Ireland), Jena University Hospital (Germany), Paris Diderot University (France) and the enterprises Biopraxis (Spain), Immupharma (UK) and Chemicell (Germany).